The function of the mitochondria – also defined as "power plants" within the cells – is essential as to whether, and how, some chemotherapeutic agents take effect in tissue. Scientists at the Helmholtz Zentrum München ...
May 10, 2013
0
0
Platinum compounds, such as cisplatin and carboplatin, induce DNA cross-linking, prohibiting DNA synthesis and repair in rapidly dividing cells. They are first line therapeutics in the treatment of many solid tumors, but ...
Apr 15, 2013
0
1
Nitric oxide (NO), a gas with many biological functions in healthy cells, can also help some cancer cells survive chemotherapy. A new study from MIT reveals one way in which this resistance may arise, and raises the possibility ...
Apr 8, 2013
0
0
Poly (ADP-ribose) polymerase inhibitors may be a novel treatment strategy for patients with cancer that has become resistant to the commonly used chemotherapy drug cisplatin, according to data from a preclinical study published ...
Apr 3, 2013
0
0
(HealthDay)—Currently available antibodies for the excision repair cross-complementation group 1 (ERCC1) protein are not adequate for therapeutic decision-making regarding the potential efficacy of cisplatin-containing ...
Mar 21, 2013
0
0
At the 28th Annual EAU Congress currently ongoing in Milan until Tuesday, W. Tan and colleagues presented their study on neoadjuvant cisplatin-based chemotherapy which showed that epigenetic changes are potential key drivers ...
Mar 18, 2013
0
0
Locally advanced squamous cell carcinoma of the head and neck is a potentially curable disease in nearly every patient at the time of diagnosis, yet despite the most aggressive efforts, up to 30-50 percent of patients may ...
Mar 7, 2013
0
0
(HealthDay)—Patients with advanced solid tumors receiving cisplatin-based chemotherapy regimens have a significantly higher risk of having a venous thromboembolic event (VTE) compared with those who do not receive a cisplatin-based ...
Nov 15, 2012
0
0
Some animal models developed by researchers at the Institute of Biomedical Research of Bellvitge (IDIBELL) and the Catalan Institute of Oncology (ICO) has served to validate the effectiveness of a new drug against ovarian ...
Oct 9, 2012
0
0
When Linda Tuttle was diagnosed with breast cancer, she never imagined her experience would inspire her colleagues to design new treatments to tackle the disease.
Oct 2, 2012
0
0
